BioStem Technologies, Inc. (BSEM)
3.43
-0.14
(-3.79%)
USD |
OTCM |
Jun 10, 16:00
BioStem Technologies Enterprise Value : 47.83M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 47.83M |
| June 09, 2026 | 50.12M |
| June 08, 2026 | 52.08M |
| June 05, 2026 | 55.75M |
| June 04, 2026 | 58.13M |
| June 03, 2026 | 59.49M |
| June 02, 2026 | 60.38M |
| June 01, 2026 | 60.62M |
| May 29, 2026 | 59.89M |
| May 28, 2026 | 56.03M |
| May 27, 2026 | 57.31M |
| May 26, 2026 | 55.98M |
| May 22, 2026 | 59.81M |
| May 21, 2026 | 59.21M |
| May 20, 2026 | 57.43M |
| May 19, 2026 | 62.44M |
| May 18, 2026 | 64.41M |
| May 15, 2026 | 62.95M |
| May 14, 2026 | 75.07M |
| May 13, 2026 | 75.77M |
| May 12, 2026 | 73.99M |
| May 11, 2026 | 66.85M |
| May 08, 2026 | 66.00M |
| May 07, 2026 | 59.38M |
| May 06, 2026 | 60.06M |
| Date | Value |
|---|---|
| May 05, 2026 | 63.80M |
| May 04, 2026 | 64.31M |
| May 01, 2026 | 65.16M |
| April 30, 2026 | 66.12M |
| April 29, 2026 | 66.82M |
| April 28, 2026 | 69.74M |
| April 27, 2026 | 67.70M |
| April 24, 2026 | 71.61M |
| April 23, 2026 | 65.16M |
| April 22, 2026 | 69.91M |
| April 21, 2026 | 68.38M |
| April 20, 2026 | 66.34M |
| April 17, 2026 | 73.99M |
| April 16, 2026 | 67.70M |
| April 15, 2026 | 69.06M |
| April 14, 2026 | 72.09M |
| April 13, 2026 | 71.61M |
| April 10, 2026 | 76.74M |
| April 09, 2026 | 77.89M |
| April 08, 2026 | 76.70M |
| April 07, 2026 | 86.22M |
| April 06, 2026 | 73.31M |
| April 02, 2026 | 67.14M |
| April 01, 2026 | 60.19M |
| March 31, 2026 | 58.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -22.81M |
| CorMedix, Inc. | 653.67M |
| Eloxx Pharmaceuticals, Inc. | -1.296M |
| Cannabis Global, Inc. | -- |
| Axsome Therapeutics, Inc. | 12.58B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.820M |
| Revenue (Quarterly) | 6.136M |
| Total Expenses (Quarterly) | 14.96M |
| EPS Diluted (Quarterly) | -0.5234 |
| Gross Profit Margin (Quarterly) | 52.47% |
| Profit Margin (Quarterly) | -143.7% |
| Earnings Yield | -34.82% |
| Normalized Earnings Yield | -34.82 |